Protection and systemic translocation of siRNA following oral administration of chitosan/siRNA nanoparticles

Molecular Therapy Nucleic Acids

Volumn 2, Issue , 2013, Pages e76-

  Ballarín González, Borja ^a   Dagnaes Hansen, Frederik ^a   Fenton, Robert A ^a   Gao, Shan ^a   Hein, San ^a   Dong, Mingdong ^a   Kjems, Jørgen ^a   Howard, Kenneth A ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Chitosan; Mucosal; Nanoparticles; Oral; SiRNA; Stability; Systemic translocation

Indexed keywords

CHITOSAN; NANOPARTICLE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ARTICLE; COLON; CONTROLLED STUDY; FEEDING; INTESTINE EPITHELIUM; KIDNEY; LIVER; MOUSE; NONHUMAN; NORTHERN BLOTTING; ORGAN DISTRIBUTION; PARTICLE SIZE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SMALL INTESTINE; SPLEEN; STOMACH;

EID: 84878887964     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.2     Document Type: Article

References (31)

1. Meister, G and Tuschl, T (2004). Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343-349. (Pubitemid 39265674)
2. Zamore, PD, Tuschl, T, Sharp, PA and Bartel, DP (2000). RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101: 25-33.
3. Davidson, BL and McCray, PB Jr (2011). Current prospects for RNA interference-based therapies. Nat Rev Genet 12: 329-340.
4. de Fougerolles, A, Vornlocher, HP, Maraganore, J and Lieberman, J (2007). Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6: 443-453. (Pubitemid 47064567)
5. Akinc, A, Zumbuehl, A, Goldberg, M, Leshchiner, ES, Busini, V, Hossain, N et al. (2008). A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26: 561-569. (Pubitemid 351668042)
6. Howard, KA, Rahbek, UL, Liu, X, Damgaard, CK, Glud, SZ, Andersen, MØ et al. (2006). RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 14: 476-484. (Pubitemid 44296092)
7. Ballarín-González, B, Nielsen, EB, Thomsen, TB, Howard, KA. (2012). Mucosal delivery of RNAi therapeutics. In: Howard, KA, (ed.). RNA Interference From Biology to Therapeutics. Advances in Delivery Science and Technology, Springer: New York, 97-125.
8. Wilson, DS, Dalmasso, G, Wang, L, Sitaraman, SV, Merlin, D, Murthy, N. (2010). Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater 9: 923-928.
9. Kriegel, C and Amiji, M (2011). Oral TNF-a gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J Control Release 150: 77-86.
10. Aouadi, M, Tesz, GJ, Nicoloro, SM, Wang, M, Chouinard, M, Soto, E et al. (2009). Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458: 1180-1184.
11. Mao, S, Sun, W and Kissel, T (2010). Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev 62: 12-27.
12. Illum, L (1998). Chitosan and its use as a pharmaceutical excipient. Pharm Res 15: 1326-1331. (Pubitemid 28427917)
13. Soane, RJ, Frier, M, Perkins, AC, Jones, NS, Davis, SS and Illum, L (1999). Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 178: 55-65. (Pubitemid 29074407)
14. Aspden, TJ, Mason, JD, Jones, NS, Lowe, J, Skaugrud, O and Illum, L (1997). Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci 86: 509-513. (Pubitemid 27154770)
15. Nielsen, EJ, Nielsen, JM, Becker, D, Karlas, A, Prakash, H, Glud, SZ et al. (2010). Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/siRNA nanoparticles. Pharm Res 27: 2520-2527.
16. Howard, KA, Paludan, SR, Behlke, MA, Besenbacher, F, Deleuran, B and Kjems, J (2009). Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther 17: 162-168.
17. Nawroth, I, Alsner, J, Behlke, MA, Besenbacher, F, Overgaard, J, Howard, KA et al. (2010). Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNFa prevents radiation-induced fibrosis. Radiother Oncol 97: 143-148.
18. Liu, X, Howard, KA, Dong, M, Andersen, MØ, Rahbek, UL, Johnsen, MG et al. (2007). The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 28: 1280-1288. (Pubitemid 44816373)
19. Morrissey, DV, Lockridge, JA, Shaw, L, Blanchard, K, Jensen, K, Breen, W et al. (2005). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23: 1002-1007. (Pubitemid 41114035)
20. Behlke, MA (2008). Chemical modification of siRNAs for in vivo use. Oligonucleotides 18: 305-319. (Pubitemid 352791344)
21. Cekaite, L, Furset, G, Hovig, E and Sioud, M (2007). Gene expression analysis in blood cells in response to unmodified and 2'-modified siRNAs reveals TLR-dependent and independent effects. J Mol Biol 365: 90-108. (Pubitemid 44830036)
22. Hornung, V, Guenthner-Biller, M, Bourquin, C, Ablasser, A, Schlee, M, Uematsu, S et al. (2005). Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11: 263-270. (Pubitemid 40460553)
23. Karikó, K, Buckstein, M, Ni, H and Weissman, D (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23: 165-175. (Pubitemid 41169286)
24. Gao, S, Dagnaes-Hansen, F, Nielsen, EJ, Wengel, J, Besenbacher, F, Howard, KA et al. (2009). The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther 17: 1225-1233.
25. Choung, S, Kim, YJ, Kim, S, Park, HO and Choi, YC (2006). Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun 342: 919-927. (Pubitemid 43320485)
26. Grünweller, A, Wyszko, E, Bieber, B, Jahnel, R, Erdmann, VA and Kurreck, J (2003). Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 31: 3185-3193. (Pubitemid 37441778)
27. Bramsen, JB, Laursen, MB, Nielsen, AF, Hansen, TB, Bus, C, Langkjaer, N et al. (2009). A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res 37: 2867-2881.
28. Elmén, J, Thonberg, H, Ljungberg, K, Frieden, M, Westergaard, M, Xu, Y et al. (2005). Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 33: 439-447. (Pubitemid 40276964)
29. Volkov, AA, Kruglova, NS, Meschaninova, MI, Venyaminova, AG, Zenkova, MA, Vlassov, VV et al. (2009). Selective protection of nuclease-sensitive sites in siRNA prolongs silencing effect. Oligonucleotides 19: 191-202.
30. Andersen, MØ, Howard, KA and Kjems, J (2009). RNAi using a chitosan/siRNA nanoparticle system: in vitro and in vivo applications. Methods Mol Biol 555: 77-86.
31. Moeller, HB, Knepper, MA and Fenton, RA (2009). Serine 269 phosphorylated aquaporin-2 is targeted to the apical membrane of collecting duct principal cells. Kidney Int 75: 295-303.